Keros Therapeutics, Inc.

KROSNASDAQHealthcareBiotechnology

$10.66- (-)1Y −19.74%

As of Oct 16, 2026 close

Market cap: $219.78M
P/E (TTM): -
Forward P/E: -
Dividend yield: -
52-week range: $9.69$22.55
Volume (live): -
Avg. volume (3M): 184.60K

Keros Therapeutics, Inc. (KROS) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for Keros Therapeutics, Inc. stock.

Analyst Consensus Rating

Investment consensus from 9 professional research analysts

Consensus Rating

Hold

Based on 9 unique analysts

Medium Confidence∞:1 Buy/Sell

Average Price Target

$18.80

+76.36% upside

Loading chart...

Strong Sell

Sell

Hold

Buy

Strong Buy

Latest KROS Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Date	Analyst	Firm	Action	Rating	Price Target
Oct 7, 2026	Ekta Bagri	Zacks Equity Research	Initiates Coverage	Buy	-
Sep 30, 2026	Zacks Equity Research	Zacks Equity Research	Initiates Coverage	Hold	-
Sep 2, 2026	Benjamin Burnett	Wells Fargo	Maintains	Buy	$18.00
Aug 25, 2026	Ahan Chakraborty	Zacks Equity Research	Initiates Coverage	Hold	-
Aug 11, 2026	Jason Zemansky	BofA Securities	Reiterates	Hold	$20.00 → $17.00 −3.00 (−15.0%)
Aug 4, 2026	Yun Zhong	Wedbush	Maintains	Hold	$16.00
Aug 4, 2026	Andres Y. Maldonado	HC Wainwright	Reiterates	Buy	$20.00
Aug 4, 2026	Matt Phipps	William Blair	Maintains	Hold	-
Aug 4, 2026	Thomas Smith	Leerink Partners	Maintains	Buy	$30.00 → $23.00 −7.00 (−23.3%)

Ekta Bagri

Zacks Equity Research

BuyInitiates Coverage

Oct 7

Zacks Equity Research

HoldInitiates Coverage

Sep 30

Benjamin Burnett

Wells Fargo

BuyMaintains

$18.00

Sep 2

Ahan Chakraborty

Zacks Equity Research

HoldInitiates Coverage

Aug 25

Jason Zemansky

BofA Securities

HoldReiterates

$20.00 → $17.00

Aug 11

Yun Zhong

Wedbush

HoldMaintains

$16.00

Aug 4

Andres Y. Maldonado

HC Wainwright

BuyReiterates

$20.00

Aug 4

Matt Phipps

William Blair

HoldMaintains

Aug 4

Thomas Smith

Leerink Partners

BuyMaintains

$30.00 → $23.00

Aug 4

Source: Professional analyst ratings and price targets from the last 90 days. Data as of Oct 7, 2026. Data sources and methodology

Frequently Asked Questions

What is the analyst consensus rating for KROS?

The analyst consensus rating for KROS is Hold, based on the latest ratings from 9 analysts over the last 90 days.

What is the average price target for KROS?

The average 12-month price target for KROS is $18.80, representing an upside of 76.4% from the Oct 16, 2026 close of $10.66.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.